|

Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

RECRUITINGSponsored by Cedars-Sinai Medical Center
Actively Recruiting
SponsorCedars-Sinai Medical Center
Started2025-04-14
Est. completion2026-04-14
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06988150

Summary

The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Men, Women, and all genders
* Individuals 18 years old or older are included.
* Patients of the study investigators and team members
* Diagnosis of pancreatic ductal adenocarcinoma
* All subjects must consent to this study
* Clinically diagnosed weight loss

Exclusion Criteria:

* Minors
* Pregnant Women
* Any records flagged "break the glass" or "research opt out."
* Patients who have received treatment for SIBO in the past 3 months

Conditions2

Pancreatic AdenocarcinomaWeight Loss

Locations1 site

Cedars-Sinai Medical Center
Los Angeles, California, 90048
Abrahm Levi310-248-8084abrahm.levi@cshs.org

Browse More Trials

Weight Loss trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.